Japan-based Taiho Pharmaceutical has signed an agreement to licence its epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor candidate TAS6417...
Read More...
The post Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology appeared first on Pharmaceutical Technology.
Original Article: Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology